Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT

<< Previous

Bullboard Posts

Next >>

Comment by dayxdayon Apr 22, 2021 1:00am

197 Views

Post# 33042810

RE:RE:RE:April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT

noeIstrlfe wrote: I'm selling this at market open, absolutley ridiculous. How can this company even consider doing a consolidation share split?! Not fair happened to me with ARHT, media years ago. Bull-garbage pumper liars gtfo

You piece of SH*t basher/shorter! trying to scare investors with incomplete info you get from news releases. assfk!
This is how you post d*mb fk!
The Company is seeking authority to complete a Potential Consolidation at a later date if and when it is in the best interests of the Company to do so, but the Board has not made a decision to implement a Potential Consolidation at this time. Even if the Potential Consolidation is approved by shareholders at the Meeting the Board will have the discretion to not proceed with the Potential Consolidation. If the Board decides to proceed with the Potential Consolidation, the purpose for doing so would be to generate interest in the Company among certain investors, to comply with the pricing policies of the TSX Venture Exchange (the “TSXV”), to improve the trading liquidity of the Common Shares and to reduce volatility in the price of the Common Shares.

In addition to shareholder approval, the Potential Consolidation is subject to the approval of the TSXV.